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Facioscapulohumeral muscular dystrophy has been genetically linked to reduced numbers (48) of D4Z4 repeats at 4q35
combined with 4A(159/161/168) DUX4 polyadenylation signal haplotype. However, we have recently reported that 1.3% of
healthy individuals carry this molecular signature and 19% of subjects affected by facioscapulohumeral muscular dystrophy do
not carry alleles with eight or fewer D4Z4 repeats. Therefore, prognosis for subjects carrying or at risk of carrying D4Z4 reduced
alleles has become more complicated. To test for additional prognostic factors, we measured the degree of motor impairment in
a large group of patients affected by facioscapulohumeral muscular dystrophy and their relatives who are carrying D4Z4 reduced
alleles. The clinical expression of motor impairment was assessed in 530 subjects, 163 probands and 367 relatives, from 176
unrelated families according to a standardized clinical score. The associations between clinical severity and size of D4Z4 allele,
degree of kinship, gender, age and 4q haplotype were evaluated. Overall, 32.2% of relatives did not display any muscle
functional impairment. This phenotype was influenced by the degree of relation with proband, because 47.1% of second-
through fifth-degree relatives were unaffected, whereas only 27.5% of first-degree family members did not show motor im-
pairment. The estimated risk of developing motor impairment by age 50 for relatives carrying a D4Z4 reduced allele with 1–3
repeats or 4–8 repeats was 88.7% and 55%, respectively. Male relatives had a mean score significantly higher than females (5.4
versus 4.0, P = 0.003). No 4q haplotype was exclusively associated with the presence of disease. In 13% of families in which
D4Z4 alleles with 4–8 repeats segregate, the diagnosis of facioscapulohumeral muscular dystrophy was reported only in one
generation. In conclusion, this large-scale analysis provides further information that should be taken into account when coun-
selling families in which a reduced allele with 4–8 D4Z4 repeats segregates. In addition, the reduced expression of disease
observed in distant relatives suggests that a family’s genetic background plays a role in the occurrence of facioscapulohumeral
muscular dystrophy. These results indicate that the identification of new susceptibility factors for this disease will require an
accurate classification of families.
Keywords: facioscapulohumeral muscular dystrophy; D4Z4 reduced allele; genotype–phenotype correlations; penetrance; disease
expression
Abbreviations: DRA = D4Z4 alleles of reduced size; FSHD = facioscapulohumeral muscular dystrophy
Introduction
Facioscapulohumeral muscular dystrophy (FSHD, OMIM #158900)
is the third most common hereditary myopathy with prevalence of
1 in 20 000 (Mostacciuolo et al., 2009). FSHD is characterized by
progressive, asymmetric atrophy and weakness of a highly select-
ive set of muscle groups (Padberg et al., 1991; Lamperti et al.,
2010; Tawil et al., 2010) and wide inter- and intra-familial vari-
ability of clinical expression (Padberg, 1982; Tawil and van der
Maarel, 2006). Age-dependent penetrance based on the presence
of the characteristic clinical signs was estimated 495% by age 20
(Lunt et al., 1989; Tawil et al., 2010). The mode of inheritance is
considered autosomal dominant (Flanigan, 2004).
A large majority of patients with FSHD carry rearrangements
occurring in a 3.3 kb tandemly repeated sequence (D4Z4) located
at the 4q subtelomeric region (Wijmenga et al., 1992; Lunt et al.,
1995a; Upadhyaya et al., 1997). These rearrangements result in
polymorphic EcoRI alleles detected by the p13E-11 probe
(Wijmenga et al., 1992; Upadhyaya et al., 1997). Early studies
of small numbers of individuals observed that both de novo and
familial patients with FSHD carry p13E-11 EcoRI alleles of 35 kb,
corresponding to eight D4Z4 units, or shorter (Griggs et al., 1993;
Lunt et al., 1995a; van Deutekom et al., 1996). For the last 20
years the clinical diagnosis of FSHD has been supported by this
type of D4Z4 DNA testing, which has been considered highly
sensitive and specific for disease (Lunt et al., 1995a, b; Lunt,
1998; Tawil et al., 2010). However, several studies on FSHD
families describe subjects carrying D4Z4 alleles of reduced size
(DRA) and no signs of the disease, defined as non-penetrant car-
riers (Tawil et al., 1996; Zatz et al., 1998; Ricci et al., 1999; van
Overveld et al., 2000; Goto et al., 2004; Tonini et al., 2004;
Sakellariou et al., 2012; Scionti et al., 2012a). As a possible ex-
planation of some non-penetrant cases, it has been proposed that
reduction of D4Z4 repeats on chromosome 4q35 is pathogenic
only in certain chromosomal backgrounds, defined by ‘permissive’
specific haplotypes, namely (i) reduction of D4Z4 elements; (ii)
presence of the 4A(159/161/168) haplotype; and (iii) a single
nucleotide polymorphism that provides a polyadenylation signal
(PAS) for the DUX4 transcript (Lemmers et al., 2002, 2007, 2010).
Nonetheless, our most recent studies (Scionti et al., 2012b)
showed that although the majority of FSHD index cases (70%)
carry DRA with 4–8 units, this size range is also carried by 3% of
healthy subjects from the general population. Additionally, our
work raised the possibility that there is little predictive value of
the 4A161PAS haplotype in the absence of family history because
1.3% of healthy subjects carry this haplotype, which is a fre-
quency similar to other common polymorphisms. Finally, we
found that 19% of FSHD probands do not carry D4Z4 alleles
with 1–8 repeats and only 50% of the probands carry the
4A161PAS permissive haplotype associated with DRA (Scionti
et al., 2012b). These observations suggest that the genetic factors
leading to FSHD might be incompletely described. Consistent with
this idea, Lemmers et al. (2012) recently described mutations in
SMCHD1 gene in patients with FSHD and hypothesized that these
mutations influence the disease penetrance (Lemmers et al.,
2012).
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Here, we evaluate FSHD occurrence among relatives carrying
DRA in relation to D4Z4 reduced allele size, gender, age, degree
of kinship and 4q haplotype.
Materials and methods
Study design and subjects selection
The study has been performed on FSHD families accrued through the
Italian National Registry for FSHD (INRF), established in 2007 by the
Italian Clinical Network for FSHD (ICNF) (www.fshd.it) (Lamperti
et al., 2010). The ICNF includes two diagnostic laboratories at the
University di Modena and Reggio Emilia and at the Fondazione
Santa Lucia in Rome and 14 clinical centres, networked within the
Italian Association of Myology (www.miologia.org) and distributed
across all of Italy, from northern to southern regions, including the
islands.
The study was conducted from 2008 to 2012. As outlined in Fig. 1,
initially the selection process regarded 418 index cases carrying DRA
with 1–8 repeats and fulfilling the clinical features of FSHD (Padberg
et al., 1991). One hundred and eighty-six cases were considered not
eligible because they had no available relatives. Fourteen compound
heterozygotes for DRA alleles were excluded from this study and ana-
lysed separately (Scionti et al., 2012a). Forty-two de novo cases,
defined as single subjects with neither parent carrying DRA, were
excluded because they would not be informative for this study. For
each proband the clinical and molecular examinations were extended
to the available relatives at various degrees of kinship. Among the 645
relatives identified, 367 were found to be carriers of DRA. All clinical
and molecular data were collected in the INRF database at Miogen
Laboratory of University of Modena for data analysis.
Clinical examination
Each subject recruited during the time of the study was examined by a
trained neurologist of the ICNF using the standardized FSHD clinical
protocol with validated inter-rater reliability (Lamperti et al., 2010).
The FSHD clinical protocol was developed by the ICNF in order to
numerically define the clinical severity of the motor impairment, and
is not to be used to diagnose FSHD. The FSHD scale quantifies muscle
weakness through the functional evaluation of six muscle groups spe-
cifically affected in FSHD, belonging to (i) face (score 0–2); (ii) shoul-
der girdle (score 0–3); (iii) upper limbs (score 0–2); (iv) distal legs
(score 0–2); (v) pelvic girdle (score 0–5); and (vi) abdominal muscles
(score 0–1). The FSHD score, which translates disability into a number,
ranges from zero, when no objective evidence of muscle functional
impairment is present, to 15, when all the muscle groups tested are
severely impaired (www.fshd.it) (Lamperti et al., 2010). DRA carriers
who did not show an objective motor impairment received an FSHD
score equal to zero and were considered clinically unaffected at the
time of examination. On the basis of the FSHD score, subjects were
classified as affected by mild (FSHD score 1–2), moderate (FSHD score
3–6), or severe (FSHD score 7–15) motor impairment.
Probands from 13 families were not re-evaluated as they were not
alive at the time of this study.
Age at onset was estimated on the basis of patient records. When
subjects did not complain of motor impairment, but a mild muscle
weakness was observed, the age at examination was set as the age
at onset, according to previous reports (Lunt et al., 1995b). In six
subjects it was not possible to obtain information about the age at
onset of motor impairment due to their poor compliance.
The study was approved by the Local Ethics Committees of all
participating Institutions. Informed consent, according to the
Declaration of Helsinki, was obtained from each subject enrolled in
the study.
Molecular characterization
Allele sizes were estimated by Southern hybridization using probe
p13E-11. Genomic DNA extracted from peripheral blood lymphocytes
was digested with EcoRI, EcoRI/BlnI or XapI, electrophoresed in a
0.4% agarose gel for 45–48 h at 35 V alongside an 8–48 kb marker
(Bio-Rad) as previously described (Scionti et al., 2012b). To assess the
chromosomal origin of D4Z4-reduced alleles, DNA from each subject
was analysed by NotI digestion and hybridization with the B31 probe
(Scionti et al., 2012b). Restriction fragments were detected by auto-
radiography or using a Typhoon Trio system (GE Healthcare). 4qA/4qB
allelic variants were defined in all 530 subjects included in the study,
using HindIII-digested DNA, pulsed field gel electrophoresis electro-
phoresis and Southern blot hybridization with radiolabeled 4qB and
4qA probes according to standard procedures (Scionti et al., 2012b).
The Simple Sequence Length Polymorphism (SSLP) and the pLAM
Single Nucleotide Polymorphism (SNP) [AT(T/C)AAA] sequences flank-
ing the D4Z4 repeat units were defined in 294 relatives according to
published procedures (Scionti et al., 2012b).
Statistical analysis
The association between the risk of being asymptomatic (FSHD score
equal to zero) and D4Z4 allele size and age was evaluated by using
the multivariate logistic regression model. The association between age
at onset or FSHD score and D4Z4 allele size and sex among symp-
tomatic relatives was assessed by using a general linear model.
Association estimates and their relative 95% confidence intervals (CI)
were also reported.
The prevalence of FSHD score, classified into two categories (0
versus 1–15), among relatives was estimated and its association with
D4Z4 allele sizes was also evaluated. Univariate and multivariate lo-
gistic regression models were fitted with D4Z4 allele size, sex and
family degree as predictors.
An interaction test was also carried out to assess whether the dif-
ference in terms of FSHD scores between probands and relatives
varied in relation to D4Z4 allele sizes.
In order to minimize any ascertainment bias, all the genotype–
phenotype correlation analyses were performed on relatives and pro-
bands separately.
In all general and generalized linear models estimated, the sandwich
estimator of covariance matrix of parameters was used to take into
account any clustering effect within families (Williams, 2000). Wald
tests were used to evaluate the effect of predictors and to evaluate the
effects of predictors on outcomes (McCullagh and Nelder, 1989).
For the cohorts of probands and family members, Kaplan-Meier
survival analysis (Kaplan and Meier, 1958) was used to estimate the
age-specific cumulative motor impairment incidence, with the corres-
ponding 95% CI. For each individual, time from birth to the earliest
age at onset of motor impairment was estimated. The analysis was
stratified by D4Z4 allele size only for relatives, and also by gender for
relatives and probands.
The risk prediction algorithm was developed and validated using
established methods (Hippisley-Cox et al., 2007). The original cohort
of 367 relatives was randomly split in the derivation and validation
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samples. The coefficients for D4Z4 allele size, sex and family degree
were estimated by using the Cox proportional hazard model. The co-
efficients were used as weights, which were combined with the base-
line survivor function to derive risk equations at age 50 years. The risk
equation was applied to the validation sample and measures of dis-
crimination were calculated (R2, D statistics and area under the re-
ceiver operating characteristic curve).
Results
We examined 530 carriers of DRA (367 relatives and 163 index
cases) from 176 unrelated families, in which at least one sub-
ject was affected by FSHD (Fig. 1B). Considering the cohort of
relatives carrying DRA as a whole (367 subjects, 152 males and
215 females, mean age 46.4  17.2, Supplementary Fig. 1), we
observed that 118 (32.2%) did not show any functional motor
impairment (FSHD score equal to zero) and 249 (67.8%) dis-
played muscle impairment to various degrees (FSHD score 51)
(Table 1).
The distribution of asymptomatic relatives was also analysed
based on the size of DRA. We divided subjects in three groups:
subjects carrying DRA with 1–3 D4Z4 repeats; subjects carrying
DRA with 4–6 D4Z4 repeats; subjects carrying DRA with 7–8
D4Z4 repeats (Supplementary Table 1 and Supplementary
Fig. 1). Table 1 also shows that 9.5% (4 out of 42) of all carriers
of DRA with 1–3 repeats displayed no motor impairment. This
percentage increases among carriers of DRA with 4–6 and 7–8
repeats (28.6% and 39.6%, respectively).
We then calculated the distribution of asymptomatic carriers
based on age at examination, separately analysing four classes:
those aged 18–30 years, 31–55 years, 56–70 years, and those
over 70 years of age (Supplementary Table 2). Four classes were
formed. As shown in Table 1, asymptomatic carriers were found in
all classes up to 70 years. In particular, almost one-third of carriers
of DRA with 4–6 and 7–8 repeats (27.6% and 35.9%, respect-
ively) were asymptomatic between 56 and 70 years of age. Since
the percentage of asymptomatic carriers varies among relatives
carrying DRA of different sizes, the age-related risk of developing
Figure 1 (A) Preliminary selection of probands/families from the Italian National Registry for FSHD (INRF). (B) Selection of the cohort of
probands and their relatives for genotype–phenotype correlation analysis.
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motor impairment was evaluated in correlation with D4Z4 size on
the basis of data obtained from 361 relatives. Figure 2 and Table 2
show the penetrance estimates for DRA carriers calculated with
the Kaplan-Meier method. Among subjects carrying DRA with 1–3
units the risk of developing motor impairment is 64.3% by age 20,
80.1% by age 40 and 96.2% by age 60. Among subjects carrying
DRA with 4–6 and 7–8 D4Z4 units these risks are 21.8% and
19.6%, respectively, by age 20, 44.8% and 42.5% by age 40,
and 71.5% and 62.9% by age 60. Therefore, FSHD penetrance is
almost complete by age 60 only for carriers of DRA with 1–3
units.
We tested whether the size of DRA correlates with age at onset
and disease severity. Table 3 shows that the mean age at onset is
statistically lower among subjects carrying DRA with 1–3 units
(20.3 years) in comparison with those carrying DRA with 4–6
and 7–8 D4Z4 repeats (29.2 and 34.6 years, respectively)
(P = 0.0002). Overall, we found that 60.6% of affected relatives
experienced scapular girdle onset, 19.0% facial muscle onset,
16.7% lower limbs onset, 0.9% upper limbs onset and 2.8%
abdominal muscle onset (Supplementary Table 3).
Severity is also increased among carriers of DRA with 1–3 re-
peats. Indeed, as shown in Table 4, affected relatives carrying
DRA with 1–3 repeats had a mean FSHD score of 7.2. By contrast,
individuals carrying DRA with 4–6 and 7–8 D4Z4 units had mean
FSHD score of 4.4 and 4.1, respectively. This association was stat-
istically significant (P = 0.0006).
The degree of motor impairment among relatives was also eval-
uated in relationship to D4Z4 allele size and age at examination.
Figure 3A shows that 40% of relatives carrying DRA with 1–3
units are severely affected (FSHD score 57) by age 30. In con-
trast, no relatives carrying DRA with 4–8 units had a FSHD score
Figure 2 Age-specific cumulative risk of reported muscle im-
pairment according to D4Z4 allele size. Estimates obtained on
361 relatives using the Kaplan-Meier analysis. Blue line refers to
carriers of 1–3 D4Z4 units; red line refers to carriers of 4–6 D4Z4
units; green line refers to carriers of 7–8 D4Z4 units. Carriers of
7–8 versus 4–6 units Log rank test P value = 0.002.
Table 1 Distribution of unaffected relatives according to D4Z4 allele size and age at examination
Age (years) Total
18–30 31–55 56–70
D4Z4 units n subjects % Score = 0 n subjects % Score = 0 n subjects % Score = 0 n subjects % Score = 0 P-value*
(n) (n) (n) (n)
1–3 8 12.5 (1) 23 8.7 (2) 9 11.1 (1) 42 9.5 (4) 0.707
4–6 31 25.8 (8) 65 33.8 (22) 29 27.6 (8) 133 28.6 (38) 0.461
7–8 42 54.8 (23) 85 40.0 (34) 39 35.9 (14) 192 39.6 (76) 0.013
Total 367 32.2 (118)
*Wald test of the age’s coefficient as ordinal predictor in the logistic model adjusted by sex.
Table 2 Estimates of the age-specific cumulative risk
obtained using the Kaplan-Meyer analysis
Age
(years)
Carriers of
1–3 D4Z4 units
Carriers of
4–6 D4Z4 units
Carriers of
7–8 D4Z4 units
Risk 95% CI Risk 95% CI Risk 95% CI
20 64.3 (50.1; 78.3) 21.8 (21.8; 37.5) 19.6 (14.6; 26.0)
30 69.1 (55.0; 82.2) 36.1 (36.1; 53.4) 35.9 (29.4; 43.5)
40 80.1 (66.5; 90.8) 44.8 (44.8; 62.5) 42.5 (35.5; 50.3)
50 88.7 (76.3; 96.3) 55.0 (55.0; 73.3) 55.7 (47.9; 63.8)
60 96.2 (84.6; 99.7) 71.5 (71.5; 88.8) 62.9 (54.7; 71.2)
70 80.3 (80.3; 97.6) 71.3 (62.3; 79.7)
80 82.2 (72.1; 90.4)
Table 3 Distribution of mean age at onset among affected
relatives according to D4Z4 allele size
Relatives
D4Z4 units Number
of subjects
Mean age
at onset
(years)
95% CI P-value†
1–3 38 20.3 15.5–25.2
4–6 91 29.2 25.6–32.7
7–8 114 34.6 30.1–39.1 0.0002
Total 243
†Wald test of equality to zero of D4Z4 allele size’s coefficients parametrized as
categorical variable in a general linear model with age at onset as dependent
variable and sex and D4Z4 allele size as predictors.
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higher than 6 in this age window. Figure 3B and C shows that
between age 31–55 and 56–70 a high percentage of relatives
carrying DRA with 4–8 units were asymptomatic (FSHD score 0)
or displayed minimal signs of functional motor impairment (FSHD
score 1–2).
We then evaluated whether there is a correlation between the
clinical status of the proband and his/her relatives. As shown in
Table 5, intra-familial analysis on 163 families with 217 affected
relatives revealed a positive correlation [0.72 (95%CI 0.40–1.04)]
in families in which D4Z4 alleles with 1–3 D4Z4 repeats segregate.
In contrast, in families with 4–6 and 7–8 D4Z4 alleles, a lower
degree of correlation between the clinical status of the proband
and his/her relatives was observed [0.01 (95%CI 0.23–0.26)
and 0.14 (95%CI 0.35–0.07), respectively].
Remarkably, in 19 of 148 families (13%) in which 4–8 D4Z4 alleles
segregate, we found affected individuals only within a single gener-
ation, and with older unaffected relatives carrying the DRA
(Supplementary Fig. 2). In each of these 19 families, molecular test-
ing excluded the presence of somatic mosaicism in the unaffected
parent carrying the DRA. The finding of affected subjects in only one
generation or the presence of only one affected subject in the entire
family suggests that a complex mode of inheritance might be at the
basis of FSHD development in these families.
To test this hypothesis we assessed whether the prevalence of
disease varies among relatives according to degree of kinship with
Table 4 Distribution of FSHD score calculated on affected
relatives according to D4Z4 allele size and age at
examination
Relatives
D4Z4 units Number
of subjects
FSHD score
mean
95% CI P-value†
1–3 38 7.2 5.8–8.6
4–6 95 4.4 3.8–5.1
7–8 116 4.1 3.5–4.7 0.0006
†Wald test of equality to zero of D4Z4 allele size and age at examination coeffi-
cients parametrized as categorical variable in a general linear model with FSHD
score as dependent variable and sex, D4Z4 allele size and age at examination as
predictors.
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Figure 3 Distribution of clinical severity among relatives carrying D4Z4 reduced allele according to D4Z4 allele size and age. Subjects
were subdivided by age: (A) 18–30 years, (B) 31–55 years, (C) 56–70 years and by D4Z4 allele size: 1–3, 4–6 and 7–8 units. In each
subgroup, percentages of subjects who received FSHD score equal to 0, 1–2, 3–6 and57 are reported.
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the proband (distribution is reported in Supplementary Table 4).
Table 6 shows that 72.5% of first-degree relatives are affected.
This percentage significantly decreases to 52.9% among relatives
with lower degree of kinship (from second- to fifth-degree), irre-
spective of D4Z4 size allele, sex and age at examination
(P = 0.018), supporting the hypothesis that beside DRA, additional
genetic factors may be necessary to develop FSHD. Conversely
47.1% of second- through fifth-degree relatives was unaffected,
while only 27.5% of first-degree family members did not show
any motor impairment.
It has also been observed that FSHD affects males more severely
and more frequently than females (Zatz et al., 1998; Tonini et al.,
2004; Sakellariou et al., 2012). We thus evaluated whether gender
influences expression and severity of motor impairment. We
observed that the percentage of asymptomatic carriers does not
significantly differ between genders (data not shown). Instead, as
shown in Table 7, male relatives had a significantly higher mean
FSHD score (5.4 versus 4.0, P = 0.003) and they developed motor
impairment on average 7.3 years before than females (P = 0.003).
Thus male relatives who develop motor impairment had a more
severe disease than affected female relatives. We then calculated
the risk of developing motor impairment between 20–50 years in
females and males separately using the Kaplan-Meier method. As
shown in Fig. 4A, the risk is higher in male relatives than females,
although the difference is not statistically significant (log rank test
P-value 0.113). Among probands the risk of developing motor
impairment after age 20 is higher in males than in females (log
rank test P-value = 0.028) (Fig. 4B). Remarkably, the risk becomes
similar between genders after age 50.
All index cases and their relatives recruited in the present study
carried the 4qA allele. As it has been recently proposed that FSHD
occurs only when DRA at 4q35 are in combination with the
4A(159/161/168)PAS haplotype (Lemmers et al., 2010), we further
characterized DNA polymorphisms flanking the D4Z4 reduced array
in 294 subjects (203 affected and 91 unaffected) belonging to 133
families from the cohort selected for this study. Table 8 reports the
various haplotypes detected. All were associated with the polyade-
nylation signal (ATTAAA) that stabilized transcripts from DUX4
gene. Notably, the 4A161PAS haplotype previously considered
‘permissive’ and the 4A166PAS haplotype previously considered
‘non-permissive’ for FSHD disease were detected in both DRA car-
riers with motor impairment (FSHD score 51) and without motor
impairment (FSHD score 0). On this basis we conclude that no spe-
cific 4q haplotype can be considered as predictive of disease.
Collectively, the statistical analysis conducted on the entire
cohort of relatives carrying DRA with 1–3 or 4–8 repeats indicates
that individuals carrying DRA with 1–3 repeats have a high risk of
developing motor impairment by age 50 (83–93%), regardless of
sex or degree of kinship. In contrast, in the group with 4–8 repeats
the reduced risk of becoming symptomatic (55-63% by age 50) is
also modulated by sex (males show a higher risk than females)
and degree of kinship (first degree relatives show a higher risk
than second-fifth degree relatives).
Discussion
Before the discovery of rearranged D4Z4 alleles, the diagnosis and
counselling of FSHD families was entirely based on clinical evi-
dence (Lunt et al., 1989). Over the years, DNA testing of the
D4Z4 locus and flanking polymorphisms has been considered
highly sensitive and specific and extensively used to diagnose
FSHD (Tawil et al., 2010). However, two recent discoveries have
challenged the current understanding of the prognostic value of
D4Z4 reduced alleles (DRA) in FSHD families: (i) alleles with
reduced numbers (48) of D4Z4 repeats at 4q35 combined with
4A(159/161/168)PAS haplotype, have a frequency of 1.3%
among healthy subjects from the general population; and (ii)
only 50% of FSHD probands carry the 4A161PAS permissive
haplotype associated with DRA (Scionti et al., 2012b).
Therefore, our understanding of the factors that cause FSHD is
incomplete and we conclude that it is crucial for clinical practice to
define further elements that can influence motor impairment and
can support the interpretation of molecular testing in FSHD
families.
The present results rely on a population-based study involving
index cases recruited from all regions of Italy. In order to minimize
any ascertainment bias the analyses were performed excluding
index cases and the evaluation of motor impairment was based
Table 5 Standardized regression coefficient between FSHD score of probands and relatives
D4Z4-allele size 1–3 D4Z4-allele size 4–6 D4Z4-allele size 7–8
Number of subjects Correlation
coefficient
95% CI Correlation
coefficient
95% CI Correlation
coefficient
95% CI P-value
217 0.72 0.40–1.04 0.01 0.23–0.26 0.14 0.35–0.07 50.0001
General linear models with FSHD score of the relative as outcome and probands’ FSHD score, age at examination, D4Z4 allele size and sex as predictors. Interaction test
between proband’s FSHD score and D4Z4 allele sizes.
Table 6 Prevalence of FSHD scores according to degree of
kinship
FSHD score
0 1–15
Degree of
kinship
Number
of subjects
% Number
of subjects
% P-valuez
First 77 27.5 203 72.5
Second/Fifth 41 47.1 46 52.9 0.018
zWald test of coefficients associated to second or third degree of kinship in logistic
models adjusted by D4Z4 allele size, sex and age at examination.
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on a standardized protocol shared within the ICNF. However,
beside these strengths, the study has some limitations. First, the
genetic background and the socio-demographic characteristics of
the Italian population might restrict the external validity of the
study results. Second, even though the study has a good coverage
of index cases, the involvement of relatives might be due to the
presence of any symptoms with the consequence that the healthy
ones might be under-represented in the study. In that case the
true estimated prevalence of disease among relatives would be
lower. Third, given that FSHD is a rare disease and no routinely
collected diagnosis records are available (Lunt et al., 1989) the
age at onset was collected retrospectively. Therefore we cannot
rule out the presence of recall bias. Indeed, the perception of
disease onset may be subjective and could depend on the specific
motor skills required in daily activities. It is thus possible that in a
number of subjects the motor impairment of limbs may be per-
ceived as early symptom because more disabling. According to
this possibility and consistent with previous works (Tawil and van
der Maarel, 2006; Pastorello et al., 2012), in our cohort the most
frequently complained symptom at onset was also the impair-
ment of upper girdle (Supplementary Table 3). Nevertheless,
we considered that patient’s complaints provide a reliable esti-
mate of the time of functional disability onset related to disease.
When subjects did not refer any motor impairment, but a mild
Figure 4 Age-specific cumulative risk of reported muscle impairment according to sex. (A) Estimates obtained on 361 relatives using the
Kaplan-Meier analysis. Log-rank test P-value = 0.113. (B) Estimates obtained on 160 probands using the Kaplan-Meier analysis. Blue line
refers to male; red line refers to female. Log-rank test P-value = 0.028.
Table 7 Distribution of FSHD score and age at onset calculated on affected relatives according to sex
FSHD Score Age at onset
Sex Number of
subjects
FSHD score
mean
95% CI P-value† Number of
subjects
Mean age at
onset (years)
95% CI P-value§
Male 102 5.4 4.7–6.1 99 26.8 (23.2; 30.5)
Female 147 4.0 3.5–4.5 0.003 144 34.1 (30.5; 37.7) 0.003
Total 249 243
†Wald test of equality to zero of female sex coefficients in a general linear model with FSHD score as dependent variable sex, D4Z4 allele size and age at examination as
predictors.
§Wald test of equality to zero of female sex coefficients in a general linear model with age at onset as dependent variable and sex and D4Z4 allele size as predictors.
Table 8 Distribution of haplotypes on 294 relatives
Relatives
4A161
(n = 204)
4A162
(n = 14)
4A163
(n = 5)
4A164
(n = 1)
4A166
(n = 69)
4A167
(n = 1)
FSHD score = 0
Number of subjects (%) 72 (79.1) 5 (5.5) 2 (2.2) 0 (0.0) 12 (13.2) 0 (0.0)
FSHD score 51
Number of subjects (%) 132 (65.0) 9 (4.4) 3 (1.5) 1 (0.5) 57 (28.1) 1 (0.5)
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muscle weakness was observed at the clinical evaluation, the age
at examination was arbitrarily set as the age at onset (Lunt et al.,
1995b).
Given these premises, our study shows that FSHD penetrance in
DRA carriers is not complete by age 20, as previously proposed
(Tawil et al., 2010), as asymptomatic carriers in all the classes of
ages up to 70 years were found.
The present analysis highlights different prognostic values of
DRA with 1–3 units when compared with DRA with 4–8 units.
First, among carriers of DRA with 1–3 units FSHD penetrance is
almost complete; in contrast, 30% of carriers of DRA with 4–8
units older than 55 years display no muscle weakness (Table 1).
Second, the estimated risk of developing motor impairment by age
50 differs between the two classes of alleles. Carriers of DRA with
1–3 units have a risk of 88.5% of developing motor impairment
by age 50; instead the risk among carriers of DRA with 4–8 units
by the same age is 55% (Fig. 2). Third, 44% of carriers of DRA
with 1–3 units develop severe FSHD (FSHD score 57) by age 55;
whereas only 24% of carriers of DRA with 4–8 units develop
disease with high degree of severity by the same age (Fig. 3B).
Fourth, the clinical phenotype is more homogeneous in families
with DRA with 1–3 units, as shown by the intra-familial analysis
(Table 5). In contrast, the clinical status of probands does not
seem to be predictive of disease severity in relatives carrying
DRA with 4–8. Importantly, in these families with DRA with 4–8
units, the penetrance of FSHD is lower as the degree of relation-
ship to the affected individual becomes more distant, indicating
that the genetic background can affect the disease outcome.
Our study also shows that gender influences disease expression,
because males are characterized by a lower mean age at onset of
motor impairment (26.8 years in males versus 34.1 years in fe-
males, Table 7) and by a more severe disability in terms of FSHD
score (5.4 in males versus 4.0 in females). Interestingly, the risk of
developing motor impairment is higher in male relatives during
adult age (range 18–55 years), whereas it is similar between
males and females in childhood/teens and elderly age (Fig. 4).
Overall, these data indicate that variables related to gender,
including genetic, hormonal, and/or lifestyle factors, may be con-
sidered and should be further investigated. Finally, our study sug-
gests that the predictive value of 4q haplotypes must be carefully
considered because no specific 4q haplotype was exclusively asso-
ciated with the presence of disease.
In summary, the genotype-phenotype correlation study pre-
sented here confirms that DRAs with 4–8 repeats have no
definitive prognostic value, and that other prognostic parameters,
beside DRAs, such as sex and degree of kinship with the pro-
band should be considered. We estimated that the risk of de-
veloping the motor impairment by age 50 in FSHD family
members is higher (83–93%) in subjects carrying DRA with
1–3 repeats. Instead, considering the cohort of relatives carrying
DRA with 4–8 repeats, the risk of developing motor impairment
is 48% for females and/or subjects with lower degree of
kinship and raises to 55–63% for males and/or subjects with
first degree of kinship with the proband. None of the various
4q haplotypes detected in FSHD families studied here were ex-
clusively associated with the presence of disease, as reported in
Table 8.
Interestingly, in our cohort, 19 of 148 FSHD families (13%) in
which a DRA with 4–8 units segregates presented affected sub-
jects only in one generation (Supplementary Fig. 2). In these
cases the lack of autosomal dominant inheritance should
prompt us to consider whether the disease develops because of
the presence of additional genetic defect(s). This possibility is sup-
ported by recent observation that mutations in the SMCHD1
gene segregate independently from the FSHD permissive D4Z4
allele on chromosome 4 in FSHD subjects that do not carry a
DRA, also defined as patients with FSHD2 (Lemmers et al.,
2012). Therefore searches for secondary FSHD loci should be
considered in all cases in which the ratio between affected and
unaffected individuals expected for an autosomal dominant dis-
ease is not observed and random association between the DRA
and FSHD cannot be excluded.
For all of these reasons, to define the predictive value of DRA, it
is necessary to carry out clinical evaluation and collection of DNA
samples of all of the proband’s family members, not only in a
research setting but also in clinical practice. We believe that
broadening the analysis of FSHD families may facilitate genetic
counselling of patients and families with FSHD in particular
when interpreting the data for prenatal diagnosis.
Acknowledgements
We are indebted to all patients with FSHD and their families for
participating in this study. The Associazione Amici del Centro Dino
Ferrari-University of Milan is gratefully acknowledged. We thank
Dr. Hulya Gundesli, Professor Woodring E. Wright and Dr. Paul D.
Kaufman for their in-depth critique of the manuscript.
Funding
This work was supported by Telethon Italy GUP08004, by
Telethon Italy GUP11009, by Association Franc¸aise contre les
Myopathies (AFM) grant number 14339 and by National
Institutes of Health (NIH)-National Institute of Neurological
Disorders and Stroke (NINDS) grant number RO1 NS047584.
Supplementary material
Supplementary material is available at Brain online.
References
Flanigan KM. Facioscapulohumeral muscular dystrophy and scapulohum-
eral syndrome. In: Engel AG, Franzini-Armstrong C, editors. Myology.
New York: McGraw-Hill; 2004. p. 123–34.
Goto K, Nishino I, Hayashi YK. Very low penetrance in 85 Japanese
families with facioscapulohumeral muscular dystrophy 1A. J Med
Genet 2004; 41: e12.
Griggs RC, Tawil R, Storvick D, Mendell JR, Altherr MR. Genetics of
facioscapulohumeral muscular dystrophy: new mutations in sporadic
cases. Neurology 1993; 43: 2369–72.
Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M,
Brindle P. Derivation and validation of QRISK, a new cardiovascular
3416 | Brain 2013: 136; 3408–3417 G. Ricci et al.
disease risk score for the United Kingdom: prospective open cohort
study. BMJ 2007; 335: 136.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observa-
tions. J Am Stat Assoc 1958; 53: 457–81.
Lamperti C, Fabbri G, Vercelli L, D’Amico R, Frusciante R, Bonifazi E,
et al. A standardized clinical evaluation of patients affected by facios-
capulohumeral muscular dystrophy: the FSHD clinical score. Muscle
Nerve 2010; 42: 213–17.
Lemmers RJ, de Kievit P, Sandkuijl L, Padberg GW, van Ommen GJ,
Frants RR, et al. Facioscapulohumeral muscular dystrophy is uniquely
associated with one of the two variants of the 4q subtelomere. Nat
Genet 2002; 32: 235–6.
Lemmers RJ, Tawil R, Petek LM, Balog J, Block GJ, Santen GW, et al.
Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive
D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2.
Nat Genet 2012; 44: 1370–4.
Lemmers RJ, van der Vliet PJ, Klooster R, Sacconi S, Caman˜o P,
Dauwerse JG, et al. A uniying genetic model for facioscapulohumeral
muscular dystrophy. Science 2010; 329: 1650–3.
Lemmers RJ, Wohlgemuth M, van der Gaag KJ, van der Vliet PJ, van
Teijlingen CM, de Knijff P, et al. Specific sequence variations within
the 4q35 region are associated with facioscapulohumeral muscular
dystrophy. Am J Hum Genet 2007; 81: 884–94.
Lunt PW, Compston DA, Harper PS. Estimation of age dependent pene-
trance in facioscapulohumeral muscular dystrophy by minimising
ascertainment bias. J Med Genet 1989; 26: 755–60.
Lunt PW, Jardine PE, Koch MC, Maynard J, Osborn M, Williams M,
et al. Correlation between fragment size at D4F104S1 and age at
onset or at wheelchair use, with a possible generational effect, ac-
counts for much phenotypic variation in 4q35-facioscapulohumeral
muscular dystrophy (FSHD). Hum Mol Genet 1995a; 4: 951–8.
Lunt PW, Jardine PE, Koch MC, Maynard J, Osborn M, Williams M,
et al. Phenotypic-genotypic correlation will assist genetic counseling
in 4q35-facioscapulohumeral muscular dystrophy. Muscle Nerve
1995b; 2: S103–9.
Lunt PW. 44th ENMC international workshop: facioscapulohumeral
muscular dystrophy: molecular studies 19–21 July 1996, Naarden,
The Netherlands. Neuromuscul Disord 1998; 8: 126–30.
McCullagh P, Nelder JA. Generalized linear models. 2nd edn. New York:
Chapman and Hall, Inc; 1989.
Mostacciuolo ML, Pastorello E, Vazza G, Miorin M, Angelini C,
Tomelleri G, et al. Facioscapulohumeral muscular dystrophy: epidemio-
logical and molecular study in a north-east Italian population sample.
Clin Genet 2009; 75: 550–55.
Padberg G. Facioscapulohumeral disease. MD thesis. University of
Leiden; 1982.
Padberg GW, Lunt PW, Koch M, Fardeau M. Diagnostic criteria for
facioscapulohumeral muscular dystrophy. Neuromuscul Disord 1991;
1: 231–4.
Pastorello E, Cao M, Trevisan CP. Atypical onset in a series of 122 cases
with facioscapulohumeral muscular dystrophy. Clin Neurol Neurosurg
2012; 114: 230–4.
Ricci E, Galluzzi G, Deidda G, Cacurri S, Colantoni L, Merico B, et al.
Progress in the molecular diagnosis of facioscapulohumeral muscular
dystrophy and correlation between the number of KpnI repeats at the
4q35 locus and clinical phenotype. Ann Neurol 1999; 45: 751–7.
Sakellariou P, Kekou K, Fryssira H, Sofocleous C, Manta P,
Panousopoulou A, et al. Mutation spectrum and phenotypic manifest-
ation in FSHD Greek patients. Neuromuscul Disord 2012; 22: 339–49.
Scionti I, Fabbri G, Fiorillo C, Ricci G, Greco F, D’Amico R, et al.
Facioscapulohumeral muscular dystrophy: new insights from com-
pound heterozygotes and implication for prenatal genetic counselling.
J Med Genet 2012a; 49: 171–8.
Scionti I, Greco F, Ricci G, Govi M, Arashiro P, Vercelli L, et al. Large
scale population analysis challenges the current criteria for the molecu-
lar diagnosis of fascioscapulohumeral muscular dystrophy (FSHD). Am
J Hum Genet 2012b; 90: 628–65.
Tawil R, Forrester J, Griggs RC, Mendell J, Kissel J, McDermott M, et al.
Evidence for anticipation and association of deletion size with severity
in facioscapulohumeral muscular dystrophy. The FSH-DY Group.
Ann Neurol 1996; 39: 744–48.
Tawil R, van der Maarel SM. Facioscapulohumeral muscular dystrophy.
Muscle Nerve 2006; 34: 1–15.
Tawil R, van der Maarel S, Padberg GW, van Engelen BG. 171st ENMC
international workshop: standards of care and management of facios-
capulohumeral muscular dystrophy. Neuromuscul Disord 2010; 20:
471–5.
Tonini MM, Passos-Bueno MR, Cerqueira A, Matioli SR, Pavanello R,
Zatz M. Asymptomatic carriers and gender differences in facioscapu-
lohumeral muscular dystrophy (FSHD). Neuromuscul Disord 2004; 14:
33–8.
Upadhyaya M, Maynard J, Rogers MT, Lunt PW, Jardine P, Ravine D,
et al. Improved molecular diagnosis of facioscapulohumeral muscular
dystrophy (FSHD): validation of the differential double digestion for
FSHD. J. Med. Genet 1997; 34: 476–9.
van Deutekom JC, Bakker E, Lemmers RJ, van der Wielen MJ, Bik E,
Hofker MH, et al. Evidence for subtelomeric exchange of 3.3 kb tan-
demly repeated units between chromosomes 4q35 and 10q26: impli-
cations for genetic counselling and etiology of FSHD1. Hum Mol
Genet 1996; 5: 1997–2003.
van Overveld PG, Lemmers RJ, Deidda G, Sandkuijl L, Padberg GW,
Frants RR, van der Maarel SM. Interchromosomal repeat array inter-
actions between chromosomes 4 and 10: a model for subtelomeric
plasticity. Hum Mol Genet 2000; 9: 2879–84.
Wijmenga C, Hewitt JE, Sandkuijl LA, Clark LN, Wright TJ,
Dauwerse HG, et al. Chromosome 4q DNA rearrangements associated
with facioscapulohumeral muscular dystrophy. Nat Genet 1992; 2:
26–30.
Williams RL. A note on robust variance estimation for cluster-correlated
data. Biometrics 2000; 56: 645–6.
Zatz M, Marie SK, Cerqueira A, Vainzof M, Pavanello RC, Passos-
Bueno MR. The facioscapulohumeral muscular dystrophy (FSHD1)
gene affects males more severely and more frequently than females.
Am J Med Genet 1998; 77: 155–61.
Prognostic tools for FSHD families Brain 2013: 136; 3408–3417 | 3417
